Insider trade

Amylyx Pharmaceuticals (AMLX): CFO sold ~$388K

James M Frates, CFO at Amylyx Pharmaceuticals, sold ~$388K of Amylyx Pharmaceuticals shares.

~$388K
Approx. value · 13K sh @ $30.32: 241K
Holds after · shares reported

Traded: Nov 10, 2026
Filed: Nov 12, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

Oct 5, 2026InsiderDirector sold ~$831K of AMLX shares in the open market
Nov 5, 2026Company filing · Form 8-K · ResultsReported its results
Nov 9, 2026Insider · 3 peopleInsiders: 6 sales (~$6.6M)
Nov 10, 2026 · this disclosureInsiderCFO sold ~$388K of AMLX shares in the open market

What came next

Nov 10, 2026InsiderCFO sold ~$223K of AMLX shares in the open market

View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Amylyx Pharmaceuticals

For Amylyx Pharmaceuticals, OQRO holds 13 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its AMLX page.

Other recent filings by James M Frates, Chief Financial Officer

The full history of James M Frates, Chief Financial Officer is on the profile page.

How this filing works

Explore the data

Other disclosures at Amylyx Pharmaceuticals

Everything OQRO holds on this company is on its AMLX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data